Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Receivables - Net: 2021-2025

Historic Receivables - Net for Tg Therapeutics (TGTX) over the last 4 years, with Sep 2025 value amounting to $265.4 million.

  • Tg Therapeutics' Receivables - Net rose 129.32% to $265.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.4 million, marking a year-over-year increase of 129.32%. This contributed to the annual value of $129.2 million for FY2024, which is 152.84% up from last year.
  • Latest data reveals that Tg Therapeutics reported Receivables - Net of $265.4 million as of Q3 2025, which was up 14.63% from $231.5 million recorded in Q2 2025.
  • Tg Therapeutics' 5-year Receivables - Net high stood at $265.4 million for Q3 2025, and its period low was $88,000 during Q2 2022.
  • Moreover, its 3-year median value for Receivables - Net was $83.6 million (2024), whereas its average is $108.8 million.
  • In the last 5 years, Tg Therapeutics' Receivables - Net slumped by 90.55% in 2022 and then skyrocketed by 19,768.18% in 2023.
  • Quarterly analysis of 5 years shows Tg Therapeutics' Receivables - Net stood at $1.4 million in 2021, then crashed by 90.55% to $88,000 in 2022, then surged by 19,768.18% to $51.1 million in 2023, then skyrocketed by 152.84% to $129.2 million in 2024, then spiked by 129.32% to $265.4 million in 2025.
  • Its Receivables - Net stands at $265.4 million for Q3 2025, versus $231.5 million for Q2 2025 and $190.1 million for Q1 2025.